#News: With @StokeTx, we announced new data from studies for an investigational medicine for Dravet Syndrome. Data were presented at the 16th European Paediatric Neurology Society Congress. Read the news here:

Biogen will report Q2 2025 financial results on July 31st before markets open in the U.S. Learn more: #Earnings $BIIB

#News: Exciting progress is underway as we begin the Phase 3 study of our investigational therapy for kidney disease in adults with primary membranous nephropathy (PMN). Learn more:

#News: We’re committed to driving innovation to help redefine what’s possible for the care of spinal muscular atrophy (SMA). We’re excited to share results from our ongoing research at the @CureSMA annual conference. Learn more about our findings:

#News: Our latest data from a phase 1 study evaluates our novel investigational SMA therapy and supports our efforts to address the needs of SMA patients. Read more about our research presented at the @CureSMA conference:

#News: We announced the initiation of the Phase 3 Pediatric Study of an investigational form of medicine for Friedreich ataxia (FA). Learn about this news:

Our CEO and leadership team shared key insights about our rare kidney disease program. As we continue to advance research, our goal is to bring additional care options to patient populations living with kidney disease. Listen now:

#News: Along with @ucb_news, we are pleased to share data from our phase 3 clinical trial evaluating our investigational lupus therapy at #EULAR2025. Read more:

#News: Today we’re hosting a virtual investor seminar to highlight the potential of our investigational therapy for a range of immune-mediated diseases, including three Phase 3 programs in rare kidney diseases. Learn more and join us at 10 a.m. ET:

Video description: Barcelona skyline with blue overlay. We look forward to sharing updates from our ongoing lupus research at EULAR 2025.

We’re heading to #EULAR2025 where we’ll share the latest updates from our ongoing lupus research!. We are excited to connect with rheumatologists & researchers to discuss the future of treatment. See how we’re addressing challenges:

Building on the success of our existing programs, we’re continuing to advance R&D efforts to help make an impact for patients. Learn about the developments in our rare disease pipeline with insights from Biogen's CEO and leadership team. Register today:

Our Head of Development attended @FTPharma to discuss the role of AI strategy in advancing our late-stage pipeline. Joining industry leaders in these discussions is vital as we continue to explore the impact of AI in biopharma.

#News: With @CityTx_ we announced a new research collaboration to develop select novel RNAi-based therapies. Learn more about this announcement:

Collaboration with other industry experts at events like @LupusCongress provides us with valuable insights to help drive progress for people living with lupus. We look forward to attending #LUPUS2025. Learn about our work:

We’re transforming what’s possible in neurology, immunology, and rare diseases by following promising science and establishing strategic partnerships. See how we’re making important progress in our pipeline to help advance health outcomes.

Our Q1 financial results support our strategy for long-term growth. We aim to bring innovative medicines to patients while generating value for our shareholders. Read more:

STARTING SOON: Join our Q1 2025 financial results live webcast at 8:30 AM ET. Join here: #Earnings $BIIB

#News: Read our Q1 2025 financial results here: #Earnings | $BIIB

#News: Our treatment for early #AlzheimersDisease with Eisai has received EU approval, advancing care options across Europe. Learn more about this milestone and what it may mean for the future of Alzheimer’s care: